Reprogramming

<h2 id="embryonic-development">Embryonic development</h2>

The mouse <a href="/facts/Sperm/RCxpXygQ">sperm</a> <a href="/facts/Genome/31Sm08JT">genome</a> is 80–90% <a href="/facts/5-Methylcytosine/mtdgxoP1">methylated</a> at its <a href="/facts/CpG_site/PbPHokwh">CpG sites</a> in DNA, amounting to about 20 million methylated sites. After <a href="/facts/Fertilization/g8u3UKzF">fertilization</a>, the paternal chromosome is almost completely <a href="/facts/DNA_demethylation/3UxQyVGy">demethylated</a> in six hours by an active process, before DNA replication (blue line in Figure). In the mature <a href="/facts/Oocyte/aYrWtc3n">oocyte</a>, about 40% of its CpG sites are methylated. Demethylation of the maternal chromosome largely takes place by blockage of the methylating <a href="/facts/Enzyme/DSI1Fh7y">enzymes</a> from acting on maternal-origin DNA and by dilution of the methylated maternal DNA during replication (red line in Figure). The <a href="/facts/Morula/PXJ8T2Ve">morula</a> (at the 16 cell stage), has only a small amount of <a href="/facts/DNA_methylation/npoRhsnX">DNA methylation</a> (black line in Figure). Methylation begins to increase at 3.5 days after fertilization in the <a href="/facts/Blastocyst/WkRkxdzc">blastocyst</a>, and a large wave of methylation then occurs on days 4.5 to 5.5 in the <a href="/facts/Epiblast/H6RSfpQy">epiblast</a>, going from 12% to 62% methylation, and reaching maximum level after implantation in the uterus.<a class="footnote-ref" id="fnref:3" href="#fn:3">3</a> By day seven after fertilization, the newly formed <a href="/facts/Germ_cell/1kY5KaR1">primordial germ cells</a> (PGC) in the implanted <a href="/facts/Embryo/9QHnLVLN">embryo</a> segregate from the remaining <a href="/facts/Somatic_cell/Emn7gk9A">somatic cells</a>. At this point the PGCs have about the same level of methylation as the somatic cells.
The newly formed primordial germ cells (PGC) in the implanted embryo devolve from the somatic cells. At this point the PGCs have high levels of methylation. These cells migrate from the epiblast toward the <a href="/facts/Gonadal_ridge/QSMF5Ifr">gonadal ridge</a>. Now the cells are rapidly proliferating and beginning demethylation in two waves. In the first wave, demethylation is by replicative dilution, but in the second wave demethylation is by an active process. The second wave leads to demethylation of specific <a href="/facts/Locus_(genetics)/JcIT8wLm">loci</a>. At this point the PGC genomes display the lowest levels of DNA methylation of any cells in the entire <a href="/facts/Biological_life_cycle/1y28aNGG">life cycle</a> [at embryonic day 13.5 (E13.5), see the second figure in this section].<a class="footnote-ref" id="fnref:4" href="#fn:4">4</a>

After fertilization some cells of the newly formed embryo migrate to the germinal ridge and will eventually become the <a href="/facts/Germ_cell/1kY5KaR1">germ cells</a> (sperm and oocytes) of the next generation. Due to the phenomenon of <a href="/facts/Genomic_imprinting/WPD8DaA4">genomic imprinting</a>, maternal and paternal genomes are differentially marked and must be properly reprogrammed every time they pass through the germline. Therefore, during the process of <a href="/facts/Gametogenesis/vgd0vV0R">gametogenesis</a> the primordial germ cells must have their original biparental <a href="/facts/DNA_methylation/npoRhsnX">DNA methylation</a> patterns erased and re-established based on the sex of the transmitting parent.
After fertilization, the paternal and maternal genomes are demethylated in order to erase their epigenetic signatures and acquire <a href="/facts/Totipotency/81323LbR">totipotency</a>. There is asymmetry at this point: the male pronucleus undergoes a quick and active demethylation. Meanwhile the female pronucleus is demethylated passively during consecutive cell divisions. The process of <a href="/facts/DNA_demethylation/3UxQyVGy">DNA demethylation</a> involves <a href="/facts/Base_excision_repair/QQIlyTxY">base excision repair</a> and likely other DNA-repair-based mechanisms.<a class="footnote-ref" id="fnref:5" href="#fn:5">5</a> Despite the global nature of this process, there are certain sequences that avoid it, such as <a href="/facts/Differentially_methylated_regions/tqCMawSL">differentially methylated regions</a> (DMRS) associated with imprinted genes, <a href="/facts/Retrotransposon/E0SgHUjT">retrotransposons</a> and <a href="/facts/Centromeric/AWxF1ClY">centromeric</a> <a href="/facts/Heterochromatin/frJ8HL41">heterochromatin</a>. Remethylation is needed again to differentiate the embryo into a complete organism.<a class="footnote-ref" id="fnref:6" href="#fn:6">6</a>
In vitro manipulation of pre-implantation embryos has been shown to disrupt methylation patterns at imprinted loci<a class="footnote-ref" id="fnref:7" href="#fn:7">7</a> and plays a crucial role in cloned animals.<a class="footnote-ref" id="fnref:8" href="#fn:8">8</a>

<h2 id="learning-and-memory">Learning and memory</h2>

<a href="/facts/Learning/lehEKRjC">Learning</a> and memory have levels of permanence, differing from other mental processes such as thought, language, and consciousness, which are temporary in nature. Learning and memory can be either accumulated slowly (multiplication tables) or rapidly (touching a hot stove), but once attained, can be recalled into conscious use for a long time. Rats subjected to one instance of <a href="/facts/Fear_conditioning/6w2xFzAA">contextual fear conditioning</a> create an especially strong long-term memory. At 24 h after training, 9.17% of the genes in the rat genomes of <a href="/facts/Hippocampus/X7CqbP8X">hippocampus</a> neurons were found to be <a href="/facts/Differentially_methylated_region/tqCMawSL">differentially methylated</a>. This included more than 2,000 differentially methylated genes at 24 hours after training, with over 500 genes being demethylated.<a class="footnote-ref" id="fnref:9" href="#fn:9">9</a> The hippocampus region of the brain is where contextual fear memories are first stored (see figure of the brain, this section), but this storage is transient and does not remain in the hippocampus. In rats contextual fear conditioning is abolished when the hippocampus is subjected to hippocampectomy just 1 day after conditioning, but rats retain a considerable amount of contextual fear when a long delay (28 days) is imposed between the time of conditioning and the time of hippocampectomy.<a class="footnote-ref" id="fnref:10" href="#fn:10">10</a>

<h2 id="molecular-stages">Molecular stages</h2>
Three molecular stages are required for reprogramming the <a href="/facts/DNA_methylation/npoRhsnX">DNA methylome</a>. Stage 1: Recruitment. The enzymes needed for reprogramming are recruited to genome sites that require demethylation or methylation. Stage 2: Implementation. The initial enzymatic reactions take place. In the case of methylation, this is a short step that results in the methylation of <a href="/facts/Cytosine/JW20j33u">cytosine</a> to <a href="/facts/5-methylcytosine/mtdgxoP1">5-methylcytosine</a>. Stage 3: <a href="/facts/Base_excision_DNA_repair/QQIlyTxY">Base excision DNA repair</a>. The intermediate products of demethylation are catalysed by specific enzymes of the base excision DNA repair pathway that finally restore cystosine in the DNA sequence.

The Figure in this section indicates the central roles of ten-eleven translocation <a href="/facts/TET_enzymes/V5oQCJBk">methylcytosine dioxygenases (TETs)</a> in the demethylation of 5-methylcytosine to form cytosine.<a class="footnote-ref" id="fnref:11" href="#fn:11">11</a> As reviewed in 2018,<a class="footnote-ref" id="fnref:12" href="#fn:12">12</a> 5mC is very often initially oxidized by TET dioxygenases to generate <a href="/facts/5-hydroxymethylcytosine/10N3TWNQ">5-hydroxymethylcytosine</a> (5hmC). In successive steps (see Figure) TET enzymes further hydroxylate 5hmC to generate <a href="/facts/5-formylcytosine/AbBJyRny">5-formylcytosine</a> (5fC) and 5-carboxylcytosine (5caC). <a href="/facts/Thymine-DNA_glycosylase/hWgILfbd">Thymine-DNA glycosylase</a> (TDG) recognizes the intermediate bases 5fC and 5caC and excises the <a href="/facts/Glycosidic_bond/xhYwU6sl">glycosidic bond</a> resulting in an <a href="/facts/AP_site/43aS1eEF">apyrimidinic site</a> (AP site). In an alternative oxidative deamination pathway, 5hmC can be oxidatively deaminated by <a href="/facts/APOBEC/ScbMzKL0">APOBEC</a> (AID/APOBEC) deaminases to form 5-hydroxymethyluracil (5hmU) or 5mC can be converted to <a href="/facts/Thymine/A5C8MnLN">thymine</a> (Thy). 5hmU can be cleaved by TDG, <a href="/facts/SMUG1/Rwy1vR3j">SMUG1</a>, <a href="/facts/NEIL1/NbjSLxFD">NEIL1</a>, or <a href="/facts/MBD4/fNYSDkza">MBD4</a>. AP sites and T:G mismatches are then repaired by base excision repair (BER) enzymes to yield cytosine (Cyt).

<h3>TET family</h3>
The isoforms of the <a href="/facts/TET_enzymes/V5oQCJBk">TET enzymes</a> include at least two isoforms of TET1, one of <a href="/facts/Tet_methylcytosine_dioxygenase_2/SFWnMbxt">TET2</a> and three isoforms of <a href="/facts/Tet_methylcytosine_dioxygenase_3/zJe1DtFt">TET3</a>.<a class="footnote-ref" id="fnref:13" href="#fn:13">13</a><a class="footnote-ref" id="fnref:14" href="#fn:14">14</a> The full-length canonical TET1 isoform appears virtually restricted to early embryos, embryonic stem cells and primordial germ cells (PGCs). The dominant TET1 isoform in most somatic tissues, at least in the mouse, arises from <a href="/facts/Alternative_promoter/YDYBzLfg">alternative promoter</a> usage which gives rise to a short transcript and a truncated protein designated TET1s. The isoforms of TET3 are the full length form TET3FL, a short form splice variant TET3s, and a form that occurs in oocytes and neurons designated TET3o. TET3o is created by alternative promoter use and contains an additional first <a href="/facts/N-terminal/yKYpuaBJ">N-terminal</a> <a href="/facts/Exon/8KWJtLuN">exon</a> coding for 11 <a href="/facts/Proteinogenic_amino_acid/xoXITvm0">amino acids</a>. TET3o only occurs in oocytes and neurons and was not expressed in embryonic stem cells or in any other cell type or adult mouse tissue tested. Whereas TET1 expression can barely be detected in oocytes and zygotes, and TET2 is only moderately expressed, the TET3 variant TET3o shows extremely high levels of expression in oocytes and zygotes, but is nearly absent at the 2-cell stage. It is possible that TET3o, high in neurons, oocytes and zygotes at the one cell stage, is the major TET enzyme utilized when very large scale rapid demethylations occur in these cells.

<h3>Recruitment of TET to DNA</h3>
The <a href="/facts/TET_enzymes/V5oQCJBk">TET enzymes</a> do not specifically bind to 5-methylcytosine except when recruited. Without recruitment or targeting, TET1 predominantly binds to high CG promoters and <a href="/facts/CpG_island/PbPHokwh">CpG islands</a> (CGIs) genome-wide by its CXXC domain that can recognize un-methylated CGIs.<a class="footnote-ref" id="fnref:15" href="#fn:15">15</a> TET2 does not have an affinity for 5-methylcytosine in DNA.<a class="footnote-ref" id="fnref:16" href="#fn:16">16</a> The CXXC domain of the full-length TET3, which is the predominant form expressed in neurons, binds most strongly to CpGs where the C was converted to 5-carboxycytosine (5caC). However, it also binds to un-methylated CpGs.<a class="footnote-ref" id="fnref:17" href="#fn:17">17</a>

For a <a href="/facts/TET_enzymes/V5oQCJBk">TET enzyme</a> to initiate demethylation it must first be recruited to a methylated <a href="/facts/CpG_site/PbPHokwh">CpG site</a> in DNA. Two of the proteins shown to recruit a TET enzyme to a methylated cytosine in DNA are <a href="/facts/Oxoguanine_glycosylase/Shefa9Cj">OGG1</a> (see figure Initiation of DNA demthylation)<a class="footnote-ref" id="fnref:18" href="#fn:18">18</a> and <a href="/facts/EGR1/nbqUEnvG">EGR1</a>.<a class="footnote-ref" id="fnref:19" href="#fn:19">19</a>

<h3>OGG1</h3>
<a href="/facts/Oxoguanine_glycosylase/Shefa9Cj">Oxoguanine glycosylase</a> (OGG1) catalyses the first step in base excision repair of the oxidatively damaged base <a href="/facts/8-Oxo-2%27-deoxyguanosine/eC6AqGY4">8-OHdG</a>. OGG1 finds 8-OHdG by sliding along the linear DNA at 1,000 base pairs of DNA in 0.1 seconds.<a class="footnote-ref" id="fnref:20" href="#fn:20">20</a> OGG1 very rapidly finds 8-OHdG. OGG1 proteins bind to oxidatively damaged DNA with a half maximum time of about 6 seconds.<a class="footnote-ref" id="fnref:21" href="#fn:21">21</a> When OGG1 finds 8-OHdG it changes conformation and complexes with 8-OHdG in the binding pocket of OGG1.<a class="footnote-ref" id="fnref:22" href="#fn:22">22</a> OGG1 does not immediately act to remove the 8-OHdG. Half maximum removal of 8-OHdG takes about 30 minutes in <a href="/facts/HeLa_cell/aP1fIhVX">HeLa cells</a> in vitro,<a class="footnote-ref" id="fnref:23" href="#fn:23">23</a> or about 11 minutes in the livers of <a href="/facts/Irradiated/fHW0QNAa">irradiated</a> mice.<a class="footnote-ref" id="fnref:24" href="#fn:24">24</a> DNA oxidation by <a href="/facts/Reactive_oxygen_species/GpwSRugH">reactive oxygen species</a> preferentially occurs at a <a href="/facts/Guanine/hoTSpz0x">guanine</a> in a methylated CpG site, because of a lowered <a href="/facts/Ionization_potential/lezUajfA">ionization potential</a> of guanine bases adjacent to 5-methylcytosine.<a class="footnote-ref" id="fnref:25" href="#fn:25">25</a> TET1 binds (is recruited to) the OGG1 bound to 8-OHdG (see figure).<a class="footnote-ref" id="fnref:26" href="#fn:26">26</a> This likely allows TET1 to demethylate an adjacent methylated cytosine. When human <a href="/facts/Mammary/6fVBnNSA">mammary</a> <a href="/facts/Epithelial_cell/ecKHcHC3">epithelial cells</a> (MCF-10A) were treated with <a href="/facts/Hydrogen_peroxide/vju6HBIc">H2O2</a>, 8-OHdG increased in DNA by 3.5-fold and this caused large scale demethylation of 5-methylcytosine to about 20% of its initial level in DNA.<a class="footnote-ref" id="fnref:27" href="#fn:27">27</a>

<h3>EGR1</h3>
The gene early growth response protein 1 (<a href="/facts/EGR1/nbqUEnvG">EGR1</a>) is an <a href="/facts/Immediate_early_gene/nlN740BC">immediate early gene</a> (IEG). The defining characteristic of IEGs is the rapid and transient up-regulation—within minutes—of their mRNA levels independent of protein synthesis.<a class="footnote-ref" id="fnref:28" href="#fn:28">28</a> EGR1 can rapidly be induced by neuronal activity.<a class="footnote-ref" id="fnref:29" href="#fn:29">29</a> In adulthood, EGR1 is expressed widely throughout the brain, maintaining baseline expression levels in several key areas of the brain including the <a href="/facts/Medial_prefrontal_cortex/dypYIrwx">medial prefrontal cortex</a>, <a href="/facts/Striatum/MjNnTjSd">striatum</a>, hippocampus and <a href="/facts/Amygdala/AAy2mHb5">amygdala</a>.<a class="footnote-ref" id="fnref:30" href="#fn:30">30</a> This expression is linked to control of cognition, emotional response, social behavior and sensitivity to reward.<a class="footnote-ref" id="fnref:31" href="#fn:31">31</a> EGR1 binds to DNA at sites with the <a href="/facts/Sequence_motif/RtcoysBD">motifs</a> 5′-GCGTGGGCG-3′ and 5'-GCGGGGGCGG-3′ and these motifs occur primarily in promoter regions of genes.<a class="footnote-ref" id="fnref:32" href="#fn:32">32</a> The short isoform TET1s is expressed in the brain. EGR1 and TET1s form a complex mediated by the <a href="/facts/C-terminal/ws4scHgT">C-terminal</a> regions of both proteins, independently of association with DNA.<a class="footnote-ref" id="fnref:33" href="#fn:33">33</a> EGR1 recruits TET1s to genomic regions flanking EGR1 binding sites.<a class="footnote-ref" id="fnref:34" href="#fn:34">34</a> In the presence of EGR1, TET1s is capable of locus-specific demethylation and activation of the expression of downstream genes regulated by EGR1.<a class="footnote-ref" id="fnref:35" href="#fn:35">35</a>

<h2 id="history">History</h2>
The first person to successfully demonstrate reprogramming was <a href="/facts/John_Gurdon/ahY231IR">John Gurdon</a>, who in 1962 demonstrated that differentiated somatic cells could be reprogrammed back into an embryonic state when he managed to obtain swimming tadpoles following the transfer of differentiated intestinal epithelial cells into enucleated frog eggs.<a class="footnote-ref" id="fnref:36" href="#fn:36">36</a> For this achievement he received the 2012 <a href="/facts/Nobel_Prize_in_Medicine/rlnpJX84">Nobel Prize in Medicine</a> alongside <a href="/facts/Shinya_Yamanaka/oqMTMwsc">Shinya Yamanaka</a>.<a class="footnote-ref" id="fnref:37" href="#fn:37">37</a> Yamanaka was the first to demonstrate (in 2006) that this somatic cell nuclear transfer or oocyte-based reprogramming process (see below), that Gurdon discovered, could be recapitulated (in mice) by defined factors (<a href="/facts/Oct4/Vee10vjH">Oct4</a>, <a href="/facts/Sox2/uKRxbGml">Sox2</a>, <a href="/facts/Klf4/v8bzjrWR">Klf4</a>, and <a href="/facts/C-Myc/7FGlAtFk">c-Myc</a>) to generate <a href="/facts/Induced_pluripotent_stem_cell/bGItax29">induced pluripotent stem cells</a> (iPSCs).<a class="footnote-ref" id="fnref:38" href="#fn:38">38</a> Other combinations of genes have also been used, including LIN25<a class="footnote-ref" id="fnref:39" href="#fn:39">39</a> and <a href="/facts/Homeobox_protein_NANOG/A66MWeBD">Homeobox protein NANOG</a>.<a class="footnote-ref" id="fnref:40" href="#fn:40">40</a><a class="footnote-ref" id="fnref:41" href="#fn:41">41</a>

<h2 id="phases-of-reprogramming">Phases of reprogramming</h2>
With the discovery that cell fate could be altered, the question of what progression of events occurs signifies a cell undergoing reprogramming. As the final product of iPSC reprogramming was similar in <a href="/facts/Morphology_(biology)/Nl3B0myy">morphology</a>, proliferation, <a href="/facts/Gene_expression/alCPohLR">gene expression</a>, <a href="/facts/Pluripotency_(biological_compounds)/HAQLJ7oH">pluripotency</a>, and <a href="/facts/Telomerase/tUtWedEg">telomerase</a> activity, genetic and morphological markers were used as a way to determine what phase of reprogramming was occurring.<a class="footnote-ref" id="fnref:42" href="#fn:42">42</a> Reprogramming is defined into three phase: initiation, maturation, and stabilization.<a class="footnote-ref" id="fnref:43" href="#fn:43">43</a>

<h3>Initiation</h3>
The initiation phase is associated with the downregulation of cell type specific genes and the upregulation of pluripotent genes.<a class="footnote-ref" id="fnref:44" href="#fn:44">44</a> As the cells move towards pluripotency, the <a href="/facts/Telomerase/tUtWedEg">telomerase</a> activity is reactivated to extend <a href="/facts/Telomere/RQ4Gp9LT">telomeres</a>. The cell morphology can directly affect the reprogramming process as the cell is modifying itself to prepare for the gene expression of pluripotency.<a class="footnote-ref" id="fnref:45" href="#fn:45">45</a> The main indicator that the initiation phase has completed is that the first genes associated with pluripotency are expressed. This includes the expression of <a href="/facts/Oct-4/Vee10vjH">Oct-4</a> or <a href="/facts/Homeobox_protein_NANOG/A66MWeBD">Homeobox protein NANOG</a>, while undergoing a <a href="/facts/Mesenchymal%E2%80%93epithelial_transition/yn6fvQjY">mesenchymal–epithelial transition</a> (MET), and the loss of <a href="/facts/Apoptosis/8dVzSm4y">apoptosis</a> and <a href="/facts/Senescence/AHmBEpe8">senescence</a>.<a class="footnote-ref" id="fnref:46" href="#fn:46">46</a> 
If the cell is directly reprogrammed from one <a href="/facts/Somatic_cell/Emn7gk9A">somatic cell</a> to another, the genes associated with each cell type begin to be upregulated and downregulated accordingly.<a class="footnote-ref" id="fnref:47" href="#fn:47">47</a> This can either occur through direct cell reprogramming or creating an intermediate, such as a iPSC, and differentiating into the desired cell type.<a class="footnote-ref" id="fnref:48" href="#fn:48">48</a> 
The initiation phase is completed through one of three pathways: <a href="/facts/Nuclear_transfer/zCAKMHcG">nuclear transfer</a>, <a href="/facts/Cell_fusion/ICG7ko46">cell fusion</a>, or defined factors (<a href="/facts/MicroRNA/UjqbYYpe">microRNA</a>, <a href="/facts/Transcription_factor/wro0DPHe">transcription factor</a>, epigenetic markers, and other small molecules).<a class="footnote-ref" id="fnref:49" href="#fn:49">49</a><a class="footnote-ref" id="fnref:50" href="#fn:50">50</a>

<h4>Somatic cell nuclear transfer</h4>
See also: <a href="/facts/Cloning/Vb6SM4c7">cloning</a>

An <a href="/facts/Oocyte/aYrWtc3n">oocyte</a> can reprogram an adult nucleus into an embryonic state after <a href="/facts/Somatic_cell_nuclear_transfer/WhD31DdC">somatic cell nuclear transfer</a>, so that a new organism can be developed from such cell.<a class="footnote-ref" id="fnref:51" href="#fn:51">51</a>
Reprogramming is distinct from development of a <a href="/facts/Somatic_epitype/hC859Djm">somatic epitype</a>,<a class="footnote-ref" id="fnref:52" href="#fn:52">52</a> as somatic epitypes can potentially be altered after an organism has left the developmental stage of life.<a class="footnote-ref" id="fnref:53" href="#fn:53">53</a> During somatic cell nuclear transfer, the oocyte turns off tissue specific genes in the somatic cell nucleus and turns back on embryonic specific genes. This process has been shown through cloning, as seen through <a href="/facts/John_Gurdon/ahY231IR">John Gurdon</a> with the tadpoles<a class="footnote-ref" id="fnref:54" href="#fn:54">54</a> and <a href="/facts/Dolly_(sheep)/P1kNJQeY">Dolly the Sheep</a>.<a class="footnote-ref" id="fnref:55" href="#fn:55">55</a> Notably, these events have shown that cell fate is a reversible process.

<h4>Cell fusion</h4>

<a class="footnote-ref" id="fnref:56" href="#fn:56">56</a>
<a href="/facts/Cell_fusion/ICG7ko46">Cell fusion</a> is used to create a multi nucleated cell called a <a href="/facts/Heterokaryon/Pjm9fo8P">heterokaryon</a>.<a class="footnote-ref" id="fnref:57" href="#fn:57">57</a> The fused cells allow for otherwise silenced genes to become reactivated and expressive. As the genes are reactivated, the cells can re-differentiate. There are instances where transcriptional factors, such as the Yamanaka factors, are still needed to aid in <a href="/facts/Heterokaryon/Pjm9fo8P">heterokaryon</a> cell reprogramming.<a class="footnote-ref" id="fnref:58" href="#fn:58">58</a>

<h4>Defined factors</h4>

Unlike nuclear transfer and cell fusion, defined factors do not require a full genome, only reprogramming factors. These reprogramming factors include <a href="/facts/MicroRNA/UjqbYYpe">microRNA</a>, <a href="/facts/Transcription_factor/wro0DPHe">transcription factor</a>, epigenetic markers, and other small molecules.<a class="footnote-ref" id="fnref:59" href="#fn:59">59</a> The original transcription factors, that lead to iPSC development, discovered by Yamanaka include <a href="/facts/Oct4/Vee10vjH">Oct4</a>, <a href="/facts/Sox2/uKRxbGml">Sox2</a>, <a href="/facts/Klf4/v8bzjrWR">Klf4</a>, and <a href="/facts/C-Myc/7FGlAtFk">c-Myc</a> (OSKM factors).<a class="footnote-ref" id="fnref:60" href="#fn:60">60</a><a class="footnote-ref" id="fnref:61" href="#fn:61">61</a> Although the OSKM factors have been shown to induce and aid in pluripotency, other transcription factors such as <a href="/facts/Homeobox_protein_NANOG/A66MWeBD">Homeobox protein NANOG</a>,<a class="footnote-ref" id="fnref:62" href="#fn:62">62</a> LIN25,<a class="footnote-ref" id="fnref:63" href="#fn:63">63</a> TRA-1-60,<a class="footnote-ref" id="fnref:64" href="#fn:64">64</a> and C/EBPα<a class="footnote-ref" id="fnref:65" href="#fn:65">65</a> aid in the efficiency of reprogramming. The use of <a href="/facts/MicroRNA/UjqbYYpe">microRNA</a> and other small molecule-driven processes has been utilized as a means of increasing the efficiency of the differentiation from somatic cells to pluripotency.<a class="footnote-ref" id="fnref:66" href="#fn:66">66</a>

<h3>Maturation</h3>
The maturation phase begins at the end of the initiation phase, when the first pluripotent genes are expressed.<a class="footnote-ref" id="fnref:67" href="#fn:67">67</a> The cell is preparing itself to be independent from the defined factors, that started the reprogramming process. The first genes to be detected in iPSCs are <a href="/facts/Oct4/Vee10vjH">Oct4</a>, <a href="/facts/Homeobox_protein_NANOG/A66MWeBD">Homeobox protein NANOG</a>, and Esrrb, followed later by <a href="/facts/Sox2/uKRxbGml">Sox2</a>.<a class="footnote-ref" id="fnref:68" href="#fn:68">68</a> In the later stages of maturation, <a href="/facts/Transgene/8DvIYSGt">transgene</a> silencing marks the start of the cell becoming independent from the induced <a href="/facts/Transcription_factor/wro0DPHe">transcription factor</a>. Once the cell is independent, the maturation phase ends and the stabilization phase begins.
As reprogramming efficiency has proven to be a variable and low efficiency process, not all the cells complete the maturation phase and achieve <a href="/facts/Pluripotency_(biological_compounds)/HAQLJ7oH">pluripotency</a>.<a class="footnote-ref" id="fnref:69" href="#fn:69">69</a> Some cells that undergo reprogramming still remain under <a href="/facts/Apoptosis/8dVzSm4y">apoptosis</a> at the beginning of the maturation stage from <a href="/facts/Oxidative_stress/HX7dfUUb">oxidative stress</a> brought on by the stresses of gene expression change. The use of <a href="/facts/MicroRNA/UjqbYYpe">microRNA</a>, proteins, and different combinations of the OSKM factors have started to lead towards a higher efficiency rate of reprogramming.

<h3>Stabilization</h3>
The stabilization phase refers to the processes in the cell that occur after the cell reaches <a href="/facts/Pluripotency_(biological_compounds)/HAQLJ7oH">pluripotency</a>. One genetic marker is the expression of <a href="/facts/Sox2/uKRxbGml">Sox2</a> and <a href="/facts/X_chromosome/hpJxhSUr">X chromosome</a> <a href="/facts/X-chromosome_reactivation/1vkrfTDu">reactivation</a>, while epigenetic changes include the <a href="/facts/Telomerase/tUtWedEg">telomerase</a> extending the <a href="/facts/Telomere/RQ4Gp9LT">telomeres</a><a class="footnote-ref" id="fnref:70" href="#fn:70">70</a> and loss of the cell’s epigenetic memory.<a class="footnote-ref" id="fnref:71" href="#fn:71">71</a> The epigenetic memory of a cell is reset by the changes in DNA methylation,<a class="footnote-ref" id="fnref:72" href="#fn:72">72</a> using <a href="/facts/Activation-induced_cytidine_deaminase/JKBrRjhl">activation-induced cytidine deaminase</a> (AID), <a href="/facts/TET_enzymes/V5oQCJBk">TET enzymes</a> (TET), and <a href="/facts/DNA_methyltransferase/NtyJN49T">DNA methyltransferase</a> (DMNTs), starting in the maturation phase and into the stabilization stage.<a class="footnote-ref" id="fnref:73" href="#fn:73">73</a> Once the epigenetic memory of the cell is lost, the possibility of differentiation into the three germ layers is achieved.<a class="footnote-ref" id="fnref:74" href="#fn:74">74</a> This is considered a fully reprogrammed cell as it can be passaged without reverting to its original somatic cell type.<a class="footnote-ref" id="fnref:75" href="#fn:75">75</a>

<h2 id="in-cell-culture-systems">In cell culture systems</h2>

Reprogramming can also be induced artificially through the introduction of exogenous factors, usually <a href="/facts/Transcription_factor/wro0DPHe">transcription factors</a>. In this context, it often refers to the creation of <a href="/facts/Induced_pluripotent_stem_cell/bGItax29">induced pluripotent stem cells</a> from mature cells such as adult <a href="/facts/Fibroblast/n08KsFll">fibroblasts</a>. This allows the production of <a href="/facts/Stem_cell/qgB9dFrI">stem cells</a> for <a href="/facts/Biomedical_research/lSVBFxDJ">biomedical research</a>, such as research into <a href="/facts/Stem-cell_therapy/dXme5FTo">stem cell therapies</a>, without the use of embryos. It is carried out by the <a href="/facts/Transfection/R94fLSQF">transfection</a> of stem-cell associated genes into mature cells using <a href="/facts/Viral_vector/sqkIdcqo">viral vectors</a> such as <a href="/facts/Retrovirus/GWAx3C3o">retroviruses</a>.

<h3>Transcription factors</h3>
One of the first transacting factors discovered to change a cell was found in a myoblast when the <a href="/facts/Complementary_DNA/P2nWeY4T">complementary DNA</a> (cDNA) coding for <a href="/facts/MyoD/p6j6fgSu">MyoD</a> was expressed and converted a <a href="/facts/Fibroblast/n08KsFll">fibroblast</a> to a myoblast. Another transacting factor that directly transformed a <a href="/facts/Lymphoid_cell/pS2pv2Ma">lymphoid cell</a> into a <a href="/facts/Myeloid_cell/VKRWVD78">myeloid cell</a> was C/EBPα. MyoD and C/EBPα are examples of a small number of single factors that can transform cells. More often, a combination of transcription factors work in conjunction to reprogram a cell.

<h4>OSKM</h4>
The OSKM factors (<a href="/facts/Oct4/Vee10vjH">Oct4</a>, <a href="/facts/Sox2/uKRxbGml">Sox2</a>, <a href="/facts/Klf4/v8bzjrWR">Klf4</a>, and <a href="/facts/C-Myc/7FGlAtFk">c-Myc</a>) were initially discovered by Yamanaka in 2006, by the induction of a mouse fibroblast into an <a href="/facts/Induced_pluripotent_stem_cell/bGItax29">induced pluripotent stem cell</a> (iPSCs).<a class="footnote-ref" id="fnref:76" href="#fn:76">76</a> Within the following year, these factors were used to induce human fibroblasts into iPSCs.<a class="footnote-ref" id="fnref:77" href="#fn:77">77</a>
<a href="/facts/Oct4/Vee10vjH">Oct4</a> is part of the core regulatory genes needed for pluripotency, as it is seen in both <a href="/facts/Embryonic_stem_cell/P1n1eS1p">embryonic stem cells</a> and tumors.<a class="footnote-ref" id="fnref:78" href="#fn:78">78</a> The use of Oct4 even in small increases allows for the start differentiation into pluripotency. Oct4 works in conjecture with Sox2 for the expression of <a href="/facts/FGF4/DFg3nVtj">FGF4</a> which could aid in differentiation. 
<a href="/facts/Sox2/uKRxbGml">Sox2</a> is a gene used in maintaining pluripotency in stem cells. Oct4 and Sox2 work together to regulate hundreds of genes utilized in pluripotency.<a class="footnote-ref" id="fnref:79" href="#fn:79">79</a> However, Sox2 is not the only possible Sox family member to participate in gene regulation with Oct4 – <a href="/facts/SOX4/wLTEDm6V">Sox4</a>, <a href="/facts/SOX11/8ovfk4aG">Sox11</a>, and <a href="/facts/SOX15/Tz9HmLcg">Sox15</a> also participate, as the Sox protein is redundant throughout the stem cell <a href="/facts/Genome/31Sm08JT">genome</a>. 
<a href="/facts/Klf4/v8bzjrWR">Klf4</a> is a transcription factor used in <a href="/facts/Cell_proliferation/Jp3hWo2t">proliferation</a>, <a href="/facts/Cellular_differentiation/bCVqUG7w">differentiation</a>, <a href="/facts/Apoptosis/8dVzSm4y">apoptosis</a>, and <a href="/facts/Somatic_cell/Emn7gk9A">somatic cell</a> reprogramming. When being utilized in cellular reprogramming, Klf4 prevents cell division of damaged cells using its apoptotic ability, and aids in <a href="/facts/Histone_acetyltransferase/gIzJY5fn">histone acetyltransferase</a> activity.<a class="footnote-ref" id="fnref:80" href="#fn:80">80</a>
<a href="/facts/C-Myc/7FGlAtFk">c-Myc</a> is also known as an <a href="/facts/Oncogene/WLFu6Ma5">oncogene</a>, and in certain conditions can become cancer causing.<a class="footnote-ref" id="fnref:81" href="#fn:81">81</a> In cellular reprogramming, c-Myc is used for <a href="/facts/Cell_cycle/nLMT7K4r">cell cycle</a> progression, <a href="/facts/Apoptosis/8dVzSm4y">apoptosis</a>, and cellular transformation for further differentiation. 

<h4>NANOG</h4>
<a href="/facts/Homeobox_protein_NANOG/A66MWeBD">Homeobox protein NANOG</a> (NANOG) is a transcription factor used to aid in the efficiency of generating iPSCs by maintaining <a href="/facts/Cell_potency/81323LbR">pluripotency</a><a class="footnote-ref" id="fnref:82" href="#fn:82">82</a> and suppressing <a href="/facts/Cell_fate_determination/5QeX65un">cell determination factors</a>.<a class="footnote-ref" id="fnref:83" href="#fn:83">83</a> NANOG works by promoting <a href="/facts/Chromatin/ha0TJheJ">chromatin</a> accessibility through repression of <a href="/facts/Histone/krb5VJfp">histone</a> markers, such as <a href="/facts/H3K27me3/KaooAT7Y">H3K27me3</a>. NANOG aids recruitment of <a href="/facts/Oct4/Vee10vjH">Oct4</a>, <a href="/facts/Sox2/uKRxbGml">Sox2</a>, and Esrrb used in <a href="/facts/Transcription_(biology)/bDgp9HDN">transcription</a>, while also recruiting <a href="/facts/SMARCA4/tTMYE8oQ">Brahma-related gene-1</a> (BRG1) for <a href="/facts/Chromatin/ha0TJheJ">chromatin</a> accessibility.

<h4>C/EBPα</h4>
<a href="/facts/CEBPA/w1Y1XzpT">CEBPA</a> is a commonly used factor when reprogramming cells into not only iPSCs, but also other cells. C/EBPα has shown itself to be a single transacting factor during direct reprogramming of a lymphoid cell into a myeloid cell.<a class="footnote-ref" id="fnref:84" href="#fn:84">84</a> C/EBPα is considered a 'path breaker' to aid in preparing the cell for intake of the OSKM factors and specific transcription events.<a class="footnote-ref" id="fnref:85" href="#fn:85">85</a> C/EBPα has also been shown to increase the efficiency of the reprogramming events.<a class="footnote-ref" id="fnref:86" href="#fn:86">86</a>

<h2 id="variability">Variability</h2>
The properties of cells obtained after reprogramming can vary significantly, in particular among iPSCs.<a class="footnote-ref" id="fnref:87" href="#fn:87">87</a> Factors leading to variation in the performance of reprogramming and functional features of end products include genetic background, tissue source, reprogramming factor stoichiometry and stressors related to cell culture.<a class="footnote-ref" id="fnref:88" href="#fn:88">88</a>

<h2 id="see-also">See also</h2>
<ul><li>Induced stem cells</li>
<li><a href="/facts/Epigenome_editing/4sDmajH3">Epigenome editing</a></li></ul>

<h2 id="references">References</h2>

<ol>
<li id="fn:1">Reik W, Dean W, Walter J (August 2001). "Epigenetic reprogramming in mammalian development". Science (Review). 293 (5532): 1089–1093. doi:10.1126/science.1063443. PMID 11498579. S2CID 17089710.Duclot F, Kabbaj M (2017). "The Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric Disorders". Frontiers in Behavioral Neuroscience. 11: 35. doi:10.3389/fnbeh.2017.00035. PMC 5337695. PMID 28321184. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:1" class="footnote-back-ref">↩</a></li>
<li id="fn:2">Cedar H, Bergman Y (July 2012). "Programming of DNA methylation patterns". Annual Review of Biochemistry. 81: 97–117. doi:10.1146/annurev-biochem-052610-091920. PMID 22404632.Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (November 2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell. 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. hdl:2433/49782. PMID 18035408. S2CID 8531539. <a href="https://zenodo.org/record/894035" target="_blank">https://zenodo.org/record/894035</a> <a href="#fnref:2" class="footnote-back-ref">↩</a></li>
<li id="fn:3">Auclair G, Guibert S, Bender A, Weber M (2014). "Ontogeny of CpG island methylation and specificity of DNMT3 methyltransferases during embryonic development in the mouse". Genome Biology. 15 (12): 545. doi:10.1186/s13059-014-0545-5. PMC 4295324. PMID 25476147. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295324" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295324</a> <a href="#fnref:3" class="footnote-back-ref">↩</a></li>
<li id="fn:4">Zeng Y, Chen T (March 2019). "DNA Methylation Reprogramming during Mammalian Development". Genes. 10 (4): 257. doi:10.3390/genes10040257. PMC 6523607. PMID 30934924. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523607" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523607</a> <a href="#fnref:4" class="footnote-back-ref">↩</a></li>
<li id="fn:5">Ladstätter S, Tachibana-Konwalski K (December 2016). "A Surveillance Mechanism Ensures Repair of DNA Lesions during Zygotic Reprogramming". Cell. 167 (7): 1774–1787.e13. doi:10.1016/j.cell.2016.11.009. PMC 5161750. PMID 27916276. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161750" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161750</a> <a href="#fnref:5" class="footnote-back-ref">↩</a></li>
<li id="fn:6">Seisenberger S, Peat JR, Hore TA, Santos F, Dean W, Reik W (January 2013). "Reprogramming DNA methylation in the mammalian life cycle: building and breaking epigenetic barriers". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 368 (1609): 20110330. doi:10.1098/rstb.2011.0330. PMC 3539359. PMID 23166394. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539359" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539359</a> <a href="#fnref:6" class="footnote-back-ref">↩</a></li>
<li id="fn:7">Mann MR, Chung YG, Nolen LD, Verona RI, Latham KE, Bartolomei MS (September 2003). "Disruption of imprinted gene methylation and expression in cloned preimplantation stage mouse embryos". Biology of Reproduction. 69 (3): 902–914. doi:10.1095/biolreprod.103.017293. PMID 12748125. <a href="https://doi.org/10.1095%2Fbiolreprod.103.017293" target="_blank">https://doi.org/10.1095%2Fbiolreprod.103.017293</a> <a href="#fnref:7" class="footnote-back-ref">↩</a></li>
<li id="fn:8">Wrenzycki C, Niemann H (December 2003). "Epigenetic reprogramming in early embryonic development: effects of in-vitro production and somatic nuclear transfer". Review. Reproductive Biomedicine Online. 7 (6): 649–656. doi:10.1016/s1472-6483(10)62087-1. PMID 14748963. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:8" class="footnote-back-ref">↩</a></li>
<li id="fn:9">Duke CG, Kennedy AJ, Gavin CF, Day JJ, Sweatt JD (July 2017). "Experience-dependent epigenomic reorganization in the hippocampus". Learning & Memory. 24 (7): 278–288. doi:10.1101/lm.045112.117. PMC 5473107. PMID 28620075. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473107" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473107</a> <a href="#fnref:9" class="footnote-back-ref">↩</a></li>
<li id="fn:10">Kim JJ, Jung MW (2006). "Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review". Neuroscience and Biobehavioral Reviews. 30 (2): 188–202. doi:10.1016/j.neubiorev.2005.06.005. PMC 4342048. PMID 16120461. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342048" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342048</a> <a href="#fnref:10" class="footnote-back-ref">↩</a></li>
<li id="fn:11">Bayraktar G, Kreutz MR (2018). "The Role of Activity-Dependent DNA Demethylation in the Adult Brain and in Neurological Disorders". Frontiers in Molecular Neuroscience. 11: 169. doi:10.3389/fnmol.2018.00169. PMC 5975432. PMID 29875631. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975432" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975432</a> <a href="#fnref:11" class="footnote-back-ref">↩</a></li>
<li id="fn:12">Bayraktar G, Kreutz MR (2018). "The Role of Activity-Dependent DNA Demethylation in the Adult Brain and in Neurological Disorders". Frontiers in Molecular Neuroscience. 11: 169. doi:10.3389/fnmol.2018.00169. PMC 5975432. PMID 29875631. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975432" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975432</a> <a href="#fnref:12" class="footnote-back-ref">↩</a></li>
<li id="fn:13">Jin SG, Zhang ZM, Dunwell TL, Harter MR, Wu X, Johnson J, et al. (January 2016). "Tet3 Reads 5-Carboxylcytosine through Its CXXC Domain and Is a Potential Guardian against Neurodegeneration". Cell Reports. 14 (3): 493–505. doi:10.1016/j.celrep.2015.12.044. PMC 4731272. PMID 26774490. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731272" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731272</a> <a href="#fnref:13" class="footnote-back-ref">↩</a></li>
<li id="fn:14">Melamed P, Yosefzon Y, David C, Tsukerman A, Pnueli L (2018). "Tet Enzymes, Variants, and Differential Effects on Function". Frontiers in Cell and Developmental Biology. 6: 22. doi:10.3389/fcell.2018.00022. PMC 5844914. PMID 29556496. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844914" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844914</a> <a href="#fnref:14" class="footnote-back-ref">↩</a></li>
<li id="fn:15">Zhang W, Xia W, Wang Q, Towers AJ, Chen J, Gao R, et al. (December 2016). "Isoform Switch of TET1 Regulates DNA Demethylation and Mouse Development". Molecular Cell. 64 (6): 1062–1073. doi:10.1016/j.molcel.2016.10.030. PMID 27916660. <a href="https://doi.org/10.1016%2Fj.molcel.2016.10.030" target="_blank">https://doi.org/10.1016%2Fj.molcel.2016.10.030</a> <a href="#fnref:15" class="footnote-back-ref">↩</a></li>
<li id="fn:16">Deplus R, Delatte B, Schwinn MK, Defrance M, Méndez J, Murphy N, et al. (March 2013). "TET2 and TET3 regulate GlcNAcylation and H3K4 methylation through OGT and SET1/COMPASS". The EMBO Journal. 32 (5): 645–655. doi:10.1038/emboj.2012.357. PMC 3590984. PMID 23353889. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590984" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590984</a> <a href="#fnref:16" class="footnote-back-ref">↩</a></li>
<li id="fn:17">Melamed P, Yosefzon Y, David C, Tsukerman A, Pnueli L (2018). "Tet Enzymes, Variants, and Differential Effects on Function". Frontiers in Cell and Developmental Biology. 6: 22. doi:10.3389/fcell.2018.00022. PMC 5844914. PMID 29556496. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844914" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844914</a> <a href="#fnref:17" class="footnote-back-ref">↩</a></li>
<li id="fn:18">Zhou X, Zhuang Z, Wang W, He L, Wu H, Cao Y, et al. (September 2016). "OGG1 is essential in oxidative stress induced DNA demethylation". Cellular Signalling. 28 (9): 1163–1171. doi:10.1016/j.cellsig.2016.05.021. PMID 27251462. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:18" class="footnote-back-ref">↩</a></li>
<li id="fn:19">Sun Z, Xu X, He J, Murray A, Sun MA, Wei X, et al. (August 2019). "EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity". Nature Communications. 10 (1): 3892. Bibcode:2019NatCo..10.3892S. doi:10.1038/s41467-019-11905-3. PMC 6715719. PMID 31467272. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719</a> <a href="#fnref:19" class="footnote-back-ref">↩</a></li>
<li id="fn:20">Blainey PC, van Oijen AM, Banerjee A, Verdine GL, Xie XS (April 2006). "A base-excision DNA-repair protein finds intrahelical lesion bases by fast sliding in contact with DNA". Proceedings of the National Academy of Sciences of the United States of America. 103 (15): 5752–5757. Bibcode:2006PNAS..103.5752B. doi:10.1073/pnas.0509723103. PMC 1458645. PMID 16585517. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1458645" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1458645</a> <a href="#fnref:20" class="footnote-back-ref">↩</a></li>
<li id="fn:21">Abdou I, Poirier GG, Hendzel MJ, Weinfeld M (January 2015). "DNA ligase III acts as a DNA strand break sensor in the cellular orchestration of DNA strand break repair". Nucleic Acids Research. 43 (2): 875–892. doi:10.1093/nar/gku1307. PMC 4333375. PMID 25539916. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333375" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333375</a> <a href="#fnref:21" class="footnote-back-ref">↩</a></li>
<li id="fn:22">van der Kemp PA, Charbonnier JB, Audebert M, Boiteux S (2004). "Catalytic and DNA-binding properties of the human Ogg1 DNA N-glycosylase/AP lyase: biochemical exploration of H270, Q315 and F319, three amino acids of the 8-oxoguanine-binding pocket". Nucleic Acids Research. 32 (2): 570–578. doi:10.1093/nar/gkh224. PMC 373348. PMID 14752045. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC373348" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC373348</a> <a href="#fnref:22" class="footnote-back-ref">↩</a></li>
<li id="fn:23">Lan L, Nakajima S, Oohata Y, Takao M, Okano S, Masutani M, et al. (September 2004). "In situ analysis of repair processes for oxidative DNA damage in mammalian cells". Proceedings of the National Academy of Sciences of the United States of America. 101 (38): 13738–13743. Bibcode:2004PNAS..10113738L. doi:10.1073/pnas.0406048101. PMC 518826. PMID 15365186. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC518826" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC518826</a> <a href="#fnref:23" class="footnote-back-ref">↩</a></li>
<li id="fn:24">Hamilton ML, Guo Z, Fuller CD, Van Remmen H, Ward WF, Austad SN, et al. (May 2001). "A reliable assessment of 8-oxo-2-deoxyguanosine levels in nuclear and mitochondrial DNA using the sodium iodide method to isolate DNA". Nucleic Acids Research. 29 (10): 2117–2126. doi:10.1093/nar/29.10.2117. PMC 55450. PMID 11353081. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC55450" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC55450</a> <a href="#fnref:24" class="footnote-back-ref">↩</a></li>
<li id="fn:25">Ming X, Matter B, Song M, Veliath E, Shanley R, Jones R, Tretyakova N (March 2014). "Mapping structurally defined guanine oxidation products along DNA duplexes: influence of local sequence context and endogenous cytosine methylation". Journal of the American Chemical Society. 136 (11): 4223–4235. doi:10.1021/ja411636j. PMC 3985951. PMID 24571128. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985951" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3985951</a> <a href="#fnref:25" class="footnote-back-ref">↩</a></li>
<li id="fn:26">Zhou X, Zhuang Z, Wang W, He L, Wu H, Cao Y, et al. (September 2016). "OGG1 is essential in oxidative stress induced DNA demethylation". Cellular Signalling. 28 (9): 1163–1171. doi:10.1016/j.cellsig.2016.05.021. PMID 27251462. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:26" class="footnote-back-ref">↩</a></li>
<li id="fn:27">Zhou X, Zhuang Z, Wang W, He L, Wu H, Cao Y, et al. (September 2016). "OGG1 is essential in oxidative stress induced DNA demethylation". Cellular Signalling. 28 (9): 1163–1171. doi:10.1016/j.cellsig.2016.05.021. PMID 27251462. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:27" class="footnote-back-ref">↩</a></li>
<li id="fn:28">Reik W, Dean W, Walter J (August 2001). "Epigenetic reprogramming in mammalian development". Science (Review). 293 (5532): 1089–1093. doi:10.1126/science.1063443. PMID 11498579. S2CID 17089710.Duclot F, Kabbaj M (2017). "The Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric Disorders". Frontiers in Behavioral Neuroscience. 11: 35. doi:10.3389/fnbeh.2017.00035. PMC 5337695. PMID 28321184. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:28" class="footnote-back-ref">↩</a></li>
<li id="fn:29">Sun Z, Xu X, He J, Murray A, Sun MA, Wei X, et al. (August 2019). "EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity". Nature Communications. 10 (1): 3892. Bibcode:2019NatCo..10.3892S. doi:10.1038/s41467-019-11905-3. PMC 6715719. PMID 31467272. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719</a> <a href="#fnref:29" class="footnote-back-ref">↩</a></li>
<li id="fn:30">Reik W, Dean W, Walter J (August 2001). "Epigenetic reprogramming in mammalian development". Science (Review). 293 (5532): 1089–1093. doi:10.1126/science.1063443. PMID 11498579. S2CID 17089710.Duclot F, Kabbaj M (2017). "The Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric Disorders". Frontiers in Behavioral Neuroscience. 11: 35. doi:10.3389/fnbeh.2017.00035. PMC 5337695. PMID 28321184. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:30" class="footnote-back-ref">↩</a></li>
<li id="fn:31">Reik W, Dean W, Walter J (August 2001). "Epigenetic reprogramming in mammalian development". Science (Review). 293 (5532): 1089–1093. doi:10.1126/science.1063443. PMID 11498579. S2CID 17089710.Duclot F, Kabbaj M (2017). "The Role of Early Growth Response 1 (EGR1) in Brain Plasticity and Neuropsychiatric Disorders". Frontiers in Behavioral Neuroscience. 11: 35. doi:10.3389/fnbeh.2017.00035. PMC 5337695. PMID 28321184. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:31" class="footnote-back-ref">↩</a></li>
<li id="fn:32">Sun Z, Xu X, He J, Murray A, Sun MA, Wei X, et al. (August 2019). "EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity". Nature Communications. 10 (1): 3892. Bibcode:2019NatCo..10.3892S. doi:10.1038/s41467-019-11905-3. PMC 6715719. PMID 31467272. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719</a> <a href="#fnref:32" class="footnote-back-ref">↩</a></li>
<li id="fn:33">Sun Z, Xu X, He J, Murray A, Sun MA, Wei X, et al. (August 2019). "EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity". Nature Communications. 10 (1): 3892. Bibcode:2019NatCo..10.3892S. doi:10.1038/s41467-019-11905-3. PMC 6715719. PMID 31467272. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719</a> <a href="#fnref:33" class="footnote-back-ref">↩</a></li>
<li id="fn:34">Sun Z, Xu X, He J, Murray A, Sun MA, Wei X, et al. (August 2019). "EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity". Nature Communications. 10 (1): 3892. Bibcode:2019NatCo..10.3892S. doi:10.1038/s41467-019-11905-3. PMC 6715719. PMID 31467272. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719</a> <a href="#fnref:34" class="footnote-back-ref">↩</a></li>
<li id="fn:35">Sun Z, Xu X, He J, Murray A, Sun MA, Wei X, et al. (August 2019). "EGR1 recruits TET1 to shape the brain methylome during development and upon neuronal activity". Nature Communications. 10 (1): 3892. Bibcode:2019NatCo..10.3892S. doi:10.1038/s41467-019-11905-3. PMC 6715719. PMID 31467272. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6715719</a> <a href="#fnref:35" class="footnote-back-ref">↩</a></li>
<li id="fn:36">Gurdon JB (December 1962). "The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles". Journal of Embryology and Experimental Morphology. 10: 622–640. PMID 13951335. <a href="/wiki/PMID_(identifier)" target="_blank">/wiki/PMID_(identifier)</a> <a href="#fnref:36" class="footnote-back-ref">↩</a></li>
<li id="fn:37">"The Nobel Prize in Physiology or Medicine – 2012 Press Release". Nobel Media AB. 8 October 2012. <a href="https://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/press.html" target="_blank">https://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/press.html</a> <a href="#fnref:37" class="footnote-back-ref">↩</a></li>
<li id="fn:38">Takahashi K, Yamanaka S (August 2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors" (PDF). Cell. 126 (4): 663–676. doi:10.1016/j.cell.2006.07.024. PMID 16904174. S2CID 1565219. <a href="/wiki/Shinya_Yamanaka" target="_blank">/wiki/Shinya_Yamanaka</a> <a href="#fnref:38" class="footnote-back-ref">↩</a></li>
<li id="fn:39">de Magalhães JP, Ocampo A (June 2022). "Cellular reprogramming and the rise of rejuvenation biotech" (PDF). Trends in Biotechnology. 40 (6): 639–642. doi:10.1016/j.tibtech.2022.01.011. PMID 35190201. S2CID 246990346. <a href="http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf" target="_blank">http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf</a> <a href="#fnref:39" class="footnote-back-ref">↩</a></li>
<li id="fn:40">de Magalhães JP, Ocampo A (June 2022). "Cellular reprogramming and the rise of rejuvenation biotech" (PDF). Trends in Biotechnology. 40 (6): 639–642. doi:10.1016/j.tibtech.2022.01.011. PMID 35190201. S2CID 246990346. <a href="http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf" target="_blank">http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf</a> <a href="#fnref:40" class="footnote-back-ref">↩</a></li>
<li id="fn:41">Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY, et al. (2007-12-06). "Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension". Pulmonary Circulation. 10 (1). doi:10.1038/stemcells.2007.124. PMC 7052475. PMID 32166015. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052475" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052475</a> <a href="#fnref:41" class="footnote-back-ref">↩</a></li>
<li id="fn:42">Cedar H, Bergman Y (July 2012). "Programming of DNA methylation patterns". Annual Review of Biochemistry. 81: 97–117. doi:10.1146/annurev-biochem-052610-091920. PMID 22404632.Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (November 2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell. 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. hdl:2433/49782. PMID 18035408. S2CID 8531539. <a href="https://zenodo.org/record/894035" target="_blank">https://zenodo.org/record/894035</a> <a href="#fnref:42" class="footnote-back-ref">↩</a></li>
<li id="fn:43">David L, Polo JM (May 2014). "Phases of reprogramming". Stem Cell Research. 12 (3): 754–761. doi:10.1016/j.scr.2014.03.007. PMID 24735951. S2CID 31759309. <a href="https://doi.org/10.1016%2Fj.scr.2014.03.007" target="_blank">https://doi.org/10.1016%2Fj.scr.2014.03.007</a> <a href="#fnref:43" class="footnote-back-ref">↩</a></li>
<li id="fn:44">David L, Polo JM (May 2014). "Phases of reprogramming". Stem Cell Research. 12 (3): 754–761. doi:10.1016/j.scr.2014.03.007. PMID 24735951. S2CID 31759309. <a href="https://doi.org/10.1016%2Fj.scr.2014.03.007" target="_blank">https://doi.org/10.1016%2Fj.scr.2014.03.007</a> <a href="#fnref:44" class="footnote-back-ref">↩</a></li>
<li id="fn:45">Downing TL, Soto J, Morez C, Houssin T, Fritz A, Yuan F, et al. (December 2013). "Biophysical regulation of epigenetic state and cell reprogramming". Nature Materials. 12 (12): 1154–1162. Bibcode:2013NatMa..12.1154D. doi:10.1038/nmat3777. PMC 9675045. PMID 24141451. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675045" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675045</a> <a href="#fnref:45" class="footnote-back-ref">↩</a></li>
<li id="fn:46">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:46" class="footnote-back-ref">↩</a></li>
<li id="fn:47">David L, Polo JM (May 2014). "Phases of reprogramming". Stem Cell Research. 12 (3): 754–761. doi:10.1016/j.scr.2014.03.007. PMID 24735951. S2CID 31759309. <a href="https://doi.org/10.1016%2Fj.scr.2014.03.007" target="_blank">https://doi.org/10.1016%2Fj.scr.2014.03.007</a> <a href="#fnref:47" class="footnote-back-ref">↩</a></li>
<li id="fn:48">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:48" class="footnote-back-ref">↩</a></li>
<li id="fn:49">de Magalhães JP, Ocampo A (June 2022). "Cellular reprogramming and the rise of rejuvenation biotech" (PDF). Trends in Biotechnology. 40 (6): 639–642. doi:10.1016/j.tibtech.2022.01.011. PMID 35190201. S2CID 246990346. <a href="http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf" target="_blank">http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf</a> <a href="#fnref:49" class="footnote-back-ref">↩</a></li>
<li id="fn:50">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:50" class="footnote-back-ref">↩</a></li>
<li id="fn:51">Hochedlinger K, Jaenisch R (June 2006). "Nuclear reprogramming and pluripotency". Nature. 441 (7097): 1061–1067. Bibcode:2006Natur.441.1061H. doi:10.1038/nature04955. PMID 16810240. S2CID 4304218. <a href="/wiki/Bibcode_(identifier)" target="_blank">/wiki/Bibcode_(identifier)</a> <a href="#fnref:51" class="footnote-back-ref">↩</a></li>
<li id="fn:52">Saygin D, Tabib T, Bittar HE, Valenzi E, Sembrat J, Chan SY, et al. (2006). "Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension". Pulmonary Circulation. 10 (1): 976. doi:10.1038/nrn2022-c1. PMC 7052475. PMID 32166015. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052475" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052475</a> <a href="#fnref:52" class="footnote-back-ref">↩</a></li>
<li id="fn:53">Mathers JC (June 2006). "Nutritional modulation of ageing: genomic and epigenetic approaches". Mechanisms of Ageing and Development. 127 (6): 584–589. doi:10.1016/j.mad.2006.01.018. PMID 16513160. S2CID 9187848. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:53" class="footnote-back-ref">↩</a></li>
<li id="fn:54">Gurdon JB (December 1962). "The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles". Journal of Embryology and Experimental Morphology. 10: 622–640. PMID 13951335. <a href="/wiki/PMID_(identifier)" target="_blank">/wiki/PMID_(identifier)</a> <a href="#fnref:54" class="footnote-back-ref">↩</a></li>
<li id="fn:55">Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH (February 1997). "Viable offspring derived from fetal and adult mammalian cells". Nature. 385 (6619): 810–813. Bibcode:1997Natur.385..810W. doi:10.1038/385810a0. PMID 9039911. <a href="/wiki/Bibcode_(identifier)" target="_blank">/wiki/Bibcode_(identifier)</a> <a href="#fnref:55" class="footnote-back-ref">↩</a></li>
<li id="fn:56">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:56" class="footnote-back-ref">↩</a></li>
<li id="fn:57">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:57" class="footnote-back-ref">↩</a></li>
<li id="fn:58">Pereira CF, Terranova R, Ryan NK, Santos J, Morris KJ, Cui W, et al. (September 2008). Roopenian DC (ed.). "Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2". PLOS Genetics. 4 (9): e1000170. doi:10.1371/journal.pgen.1000170. PMC 2527997. PMID 18773085. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527997" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527997</a> <a href="#fnref:58" class="footnote-back-ref">↩</a></li>
<li id="fn:59">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:59" class="footnote-back-ref">↩</a></li>
<li id="fn:60">Takahashi K, Yamanaka S (August 2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors" (PDF). Cell. 126 (4): 663–676. doi:10.1016/j.cell.2006.07.024. PMID 16904174. S2CID 1565219. <a href="/wiki/Shinya_Yamanaka" target="_blank">/wiki/Shinya_Yamanaka</a> <a href="#fnref:60" class="footnote-back-ref">↩</a></li>
<li id="fn:61">Cedar H, Bergman Y (July 2012). "Programming of DNA methylation patterns". Annual Review of Biochemistry. 81: 97–117. doi:10.1146/annurev-biochem-052610-091920. PMID 22404632.Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (November 2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell. 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. hdl:2433/49782. PMID 18035408. S2CID 8531539. <a href="https://zenodo.org/record/894035" target="_blank">https://zenodo.org/record/894035</a> <a href="#fnref:61" class="footnote-back-ref">↩</a></li>
<li id="fn:62">Bueno C, Sardina JL, Di Stefano B, Romero-Moya D, Muñoz-López A, Ariza L, et al. (March 2016). "Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα". Leukemia. 30 (3): 674–682. doi:10.1038/leu.2015.294. hdl:10651/43469. PMID 26500142. S2CID 508334. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:62" class="footnote-back-ref">↩</a></li>
<li id="fn:63">de Magalhães JP, Ocampo A (June 2022). "Cellular reprogramming and the rise of rejuvenation biotech" (PDF). Trends in Biotechnology. 40 (6): 639–642. doi:10.1016/j.tibtech.2022.01.011. PMID 35190201. S2CID 246990346. <a href="http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf" target="_blank">http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf</a> <a href="#fnref:63" class="footnote-back-ref">↩</a></li>
<li id="fn:64">Bueno C, Sardina JL, Di Stefano B, Romero-Moya D, Muñoz-López A, Ariza L, et al. (March 2016). "Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα". Leukemia. 30 (3): 674–682. doi:10.1038/leu.2015.294. hdl:10651/43469. PMID 26500142. S2CID 508334. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:64" class="footnote-back-ref">↩</a></li>
<li id="fn:65">Srivastava D, DeWitt N (September 2016). "In Vivo Cellular Reprogramming: The Next Generation". Cell. 166 (6): 1386–1396. doi:10.1016/j.cell.2016.08.055. PMC 6234007. PMID 27610565. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234007" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234007</a> <a href="#fnref:65" class="footnote-back-ref">↩</a></li>
<li id="fn:66">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:66" class="footnote-back-ref">↩</a></li>
<li id="fn:67">David L, Polo JM (May 2014). "Phases of reprogramming". Stem Cell Research. 12 (3): 754–761. doi:10.1016/j.scr.2014.03.007. PMID 24735951. S2CID 31759309. <a href="https://doi.org/10.1016%2Fj.scr.2014.03.007" target="_blank">https://doi.org/10.1016%2Fj.scr.2014.03.007</a> <a href="#fnref:67" class="footnote-back-ref">↩</a></li>
<li id="fn:68">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:68" class="footnote-back-ref">↩</a></li>
<li id="fn:69">Srivastava D, DeWitt N (September 2016). "In Vivo Cellular Reprogramming: The Next Generation". Cell. 166 (6): 1386–1396. doi:10.1016/j.cell.2016.08.055. PMC 6234007. PMID 27610565. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234007" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234007</a> <a href="#fnref:69" class="footnote-back-ref">↩</a></li>
<li id="fn:70">de Magalhães JP, Ocampo A (June 2022). "Cellular reprogramming and the rise of rejuvenation biotech" (PDF). Trends in Biotechnology. 40 (6): 639–642. doi:10.1016/j.tibtech.2022.01.011. PMID 35190201. S2CID 246990346. <a href="http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf" target="_blank">http://pure-oai.bham.ac.uk/ws/files/170576357/rejuvenation_TIB_revised.pdf</a> <a href="#fnref:70" class="footnote-back-ref">↩</a></li>
<li id="fn:71">David L, Polo JM (May 2014). "Phases of reprogramming". Stem Cell Research. 12 (3): 754–761. doi:10.1016/j.scr.2014.03.007. PMID 24735951. S2CID 31759309. <a href="https://doi.org/10.1016%2Fj.scr.2014.03.007" target="_blank">https://doi.org/10.1016%2Fj.scr.2014.03.007</a> <a href="#fnref:71" class="footnote-back-ref">↩</a></li>
<li id="fn:72">Polo JM, Anderssen E, Walsh RM, Schwarz BA, Nefzger CM, Lim SM, et al. (December 2012). "A molecular roadmap of reprogramming somatic cells into iPS cells". Cell. 151 (7): 1617–1632. doi:10.1016/j.cell.2012.11.039. PMC 3608203. PMID 23260147. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608203" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608203</a> <a href="#fnref:72" class="footnote-back-ref">↩</a></li>
<li id="fn:73">David L, Polo JM (May 2014). "Phases of reprogramming". Stem Cell Research. 12 (3): 754–761. doi:10.1016/j.scr.2014.03.007. PMID 24735951. S2CID 31759309. <a href="https://doi.org/10.1016%2Fj.scr.2014.03.007" target="_blank">https://doi.org/10.1016%2Fj.scr.2014.03.007</a> <a href="#fnref:73" class="footnote-back-ref">↩</a></li>
<li id="fn:74">Cedar H, Bergman Y (July 2012). "Programming of DNA methylation patterns". Annual Review of Biochemistry. 81: 97–117. doi:10.1146/annurev-biochem-052610-091920. PMID 22404632.Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (November 2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell. 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. hdl:2433/49782. PMID 18035408. S2CID 8531539. <a href="https://zenodo.org/record/894035" target="_blank">https://zenodo.org/record/894035</a> <a href="#fnref:74" class="footnote-back-ref">↩</a></li>
<li id="fn:75">Pires CF, Rosa FF, Kurochkin I, Pereira CF (2019-12-11). "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology. 10: 2809. doi:10.3389/fimmu.2019.02809. PMC 917620. PMID 31921109. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC917620</a> <a href="#fnref:75" class="footnote-back-ref">↩</a></li>
<li id="fn:76">Takahashi K, Yamanaka S (August 2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors" (PDF). Cell. 126 (4): 663–676. doi:10.1016/j.cell.2006.07.024. PMID 16904174. S2CID 1565219. <a href="/wiki/Shinya_Yamanaka" target="_blank">/wiki/Shinya_Yamanaka</a> <a href="#fnref:76" class="footnote-back-ref">↩</a></li>
<li id="fn:77">Cedar H, Bergman Y (July 2012). "Programming of DNA methylation patterns". Annual Review of Biochemistry. 81: 97–117. doi:10.1146/annurev-biochem-052610-091920. PMID 22404632.Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (November 2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell. 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. hdl:2433/49782. PMID 18035408. S2CID 8531539. <a href="https://zenodo.org/record/894035" target="_blank">https://zenodo.org/record/894035</a> <a href="#fnref:77" class="footnote-back-ref">↩</a></li>
<li id="fn:78">Rizzino A (December 2009). "Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells". Wiley Interdisciplinary Reviews. Systems Biology and Medicine. 1 (2): 228–236. doi:10.1002/wsbm.12. PMC 2794141. PMID 20016762. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794141" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794141</a> <a href="#fnref:78" class="footnote-back-ref">↩</a></li>
<li id="fn:79">Rizzino A (December 2009). "Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells". Wiley Interdisciplinary Reviews. Systems Biology and Medicine. 1 (2): 228–236. doi:10.1002/wsbm.12. PMC 2794141. PMID 20016762. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794141" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2794141</a> <a href="#fnref:79" class="footnote-back-ref">↩</a></li>
<li id="fn:80">Cedar H, Bergman Y (July 2012). "Programming of DNA methylation patterns". Annual Review of Biochemistry. 81: 97–117. doi:10.1146/annurev-biochem-052610-091920. PMID 22404632.Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (November 2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors". Cell. 131 (5): 861–872. doi:10.1016/j.cell.2007.11.019. hdl:2433/49782. PMID 18035408. S2CID 8531539. <a href="https://zenodo.org/record/894035" target="_blank">https://zenodo.org/record/894035</a> <a href="#fnref:80" class="footnote-back-ref">↩</a></li>
<li id="fn:81">Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, et al. (July 2007). "Non-transcriptional control of DNA replication by c-Myc". Nature. 448 (7152): 445–451. Bibcode:2007Natur.448..445D. doi:10.1038/nature05953. PMID 17597761. S2CID 4422771. <a href="/wiki/Bibcode_(identifier)" target="_blank">/wiki/Bibcode_(identifier)</a> <a href="#fnref:81" class="footnote-back-ref">↩</a></li>
<li id="fn:82">Zaehres H, Lensch MW, Daheron L, Stewart SA, Itskovitz-Eldor J, Daley GQ (March 2005). "High-efficiency RNA interference in human embryonic stem cells". Stem Cells. 23 (3): 299–305. doi:10.1634/stemcells.2004-0252. PMID 15749924. S2CID 1395518. <a href="https://doi.org/10.1634%2Fstemcells.2004-0252" target="_blank">https://doi.org/10.1634%2Fstemcells.2004-0252</a> <a href="#fnref:82" class="footnote-back-ref">↩</a></li>
<li id="fn:83">Heurtier V, Owens N, Gonzalez I, Mueller F, Proux C, Mornico D, et al. (March 2019). "The molecular logic of Nanog-induced self-renewal in mouse embryonic stem cells". Nature Communications. 10 (1): 1109. Bibcode:2019NatCo..10.1109H. doi:10.1038/s41467-019-09041-z. PMC 6406003. PMID 30846691. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406003" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406003</a> <a href="#fnref:83" class="footnote-back-ref">↩</a></li>
<li id="fn:84">Srivastava D, DeWitt N (September 2016). "In Vivo Cellular Reprogramming: The Next Generation". Cell. 166 (6): 1386–1396. doi:10.1016/j.cell.2016.08.055. PMC 6234007. PMID 27610565. <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234007" target="_blank">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234007</a> <a href="#fnref:84" class="footnote-back-ref">↩</a></li>
<li id="fn:85">Bueno C, Sardina JL, Di Stefano B, Romero-Moya D, Muñoz-López A, Ariza L, et al. (March 2016). "Reprogramming human B cells into induced pluripotent stem cells and its enhancement by C/EBPα". Leukemia. 30 (3): 674–682. doi:10.1038/leu.2015.294. hdl:10651/43469. PMID 26500142. S2CID 508334. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:85" class="footnote-back-ref">↩</a></li>
<li id="fn:86">David L, Polo JM (May 2014). "Phases of reprogramming". Stem Cell Research. 12 (3): 754–761. doi:10.1016/j.scr.2014.03.007. PMID 24735951. S2CID 31759309. <a href="https://doi.org/10.1016%2Fj.scr.2014.03.007" target="_blank">https://doi.org/10.1016%2Fj.scr.2014.03.007</a> <a href="#fnref:86" class="footnote-back-ref">↩</a></li>
<li id="fn:87">Paull D, Sevilla A, Zhou H, Hahn AK, Kim H, Napolitano C, et al. (September 2015). "Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells". Nature Methods. 12 (9): 885–892. doi:10.1038/nmeth.3507. PMID 26237226. S2CID 9889991. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:87" class="footnote-back-ref">↩</a></li>
<li id="fn:88">Paull D, Sevilla A, Zhou H, Hahn AK, Kim H, Napolitano C, et al. (September 2015). "Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells". Nature Methods. 12 (9): 885–892. doi:10.1038/nmeth.3507. PMID 26237226. S2CID 9889991. <a href="/wiki/Doi_(identifier)" target="_blank">/wiki/Doi_(identifier)</a> <a href="#fnref:88" class="footnote-back-ref">↩</a></li>
</ol>

Reprogramming open-in-new

Reprogramming